Sinovac Biotech, Ltd. - Ordinary Shares (Antigua/Barbudo) (SVA) earnings
Quarterly and annual SVA reports and results, each read against the price at its own news timestamp. Back to the SVA overview →
5 measured SVA earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F | Press release | — | — | |
| SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report | Press release | — | — | |
| SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024 | Press release | — | — | |
| SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report | Press release | — | — | |
| SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F | Press release | — | — |
Keep exploring
More SVA: analyst actions → · SEC filings → · SVA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BioPlus Acquisition Corp. (BIOS) | 822 | 0.00% | 47% |
| CYTRX CORP (CYTR) | 821 | -0.00% | 43% |
| Atara Biotherapeutics, Inc. (ATRA) | 813 | -0.27% | 45% |
| Ionis Pharmaceuticals, Inc. (IONS) | 811 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.